Interpreting US Lab Reports: A Pharmacist's Guide to Common US Lab Values (e.g., A1C, INR, BMP), And Which Drugs Affect Them.

Interpreting US Lab Reports: A Pharmacist’s Guide to Common US Lab Values (e.g., A1C, INR, BMP), And Which Drugs Affect Them.

by

Lab reports are more than numbers. They tell you how a patient’s drugs are working, whether a dose is safe, and when a regimen needs to change. Pharmacists add value by knowing which medications move each lab, why the change happens, and when to act. This guide focuses on common US labs—A1C, INR, BMP—and expands to other panels you’ll see every day, with practical drug examples and quick checks.

How to read US lab reports (fast)

Know the reference range. Ranges vary by lab and method. Always compare to the lab’s listed range.

Look at trends. One abnormal value can be noise. Repeated change in the same direction often signals a real effect or toxicity.

Check timing and context. Fasting vs non-fasting, time since last dose, hydration, and sample quality (hemolysis) all matter.

Ask: could a drug explain this? Many “abnormal” results are drug effects or assay interference, not disease.

A1C: 3‑month glucose average

What it is: Percent of hemoglobin with glucose attached. Reflects the last ~8–12 weeks, weighted to recent weeks. A typical target is about 7%, individualized by age, comorbidities, and hypoglycemia risk.

Why it moves: Anything that raises average glucose (steroids, atypical antipsychotics) increases A1C. Faster red cell turnover lowers A1C by reducing exposure time to glucose.

  • Drugs that increase A1C/glucose: Glucocorticoids, tacrolimus/cyclosporine, atypical antipsychotics (e.g., olanzapine), beta-agonists (high dose), protease inhibitors, niacin.
  • Drugs that lower A1C/glucose: Insulins, metformin, GLP‑1 RAs, SGLT2 inhibitors, sulfonylureas, thiazolidinediones.
  • Conditions that distort A1C (not true glycemia): Hemolysis, acute blood loss, recent transfusion, CKD with erythropoietin use, iron/B12 deficiency (can falsely elevate until corrected), sickle trait (assay dependent).

What to do: If A1C does not match home glucose readings, check for anemia/transfusions and consider a fructosamine or CGM review. Always review recent steroid tapers or new psych meds.

INR and coagulation tests

What INR means: Standardized prothrombin time. It measures the vitamin K–dependent clotting pathway and is used to dose warfarin. Typical targets: 2.0–3.0 for AF/VTE; 2.5–3.5 for some mechanical valves.

  • Drugs that increase INR (bleeding risk): Amiodarone, azoles (fluconazole), macrolides (erythromycin), metronidazole, TMP‑SMX, fluoroquinolones, many antibiotics via gut flora vitamin K depletion; acute alcohol binge; thyroid hormone initiation (increases warfarin effect).
  • Drugs that decrease INR (clotting risk): Rifampin, carbamazepine, phenytoin (late), St. John’s wort, chronic alcohol use; vitamin K intake or supplements; hypothyroidism.
  • Not for DOACs: Apixaban, rivaroxaban, dabigatran do not use INR for dosing; INR may be slightly elevated but is not reliable.
  • aPTT/anti‑Xa: Unfractionated heparin prolongs aPTT; LMWH is monitored with anti‑Xa in special cases (pregnancy, obesity, renal impairment).
  • Liver disease: Raises INR by reducing clotting factor synthesis; not a warfarin effect.

What to do: With big INR swings, screen for new meds (especially antibiotics), diet changes, adherence, and alcohol. For expected interactions (e.g., starting amiodarone), pre‑emptively lower warfarin dose and monitor more often.

BMP: electrolytes, renal markers, and glucose

What’s included: Sodium, potassium, chloride, bicarbonate (CO₂), BUN, creatinine/eGFR, glucose, and often calcium. Each tells you about volume status, acid–base, renal function, and drug safety.

  • Sodium (Na)
    • Why it moves: Reflects water balance more than salt. Low Na often means too much free water (SIADH) or diuretic effect.
    • Drugs lowering Na: Thiazides, SSRIs/SNRIs, carbamazepine/oxcarbazepine, desmopressin, MDMA, cyclophosphamide.
    • Drugs raising Na: Lithium can cause nephrogenic DI (free water loss). Hypertonic saline or severe osmotic diuresis can raise Na.
    • What to do: In thiazide‑induced hyponatremia, stop thiazide, restrict free water, consider switching to loop diuretic if needed for BP.
  • Potassium (K)
    • Why it moves: Balance of intake, renal excretion, and shifts between cells. Acidosis and insulin deficiency move K out of cells.
    • Drugs raising K: ACE inhibitors, ARBs, ARNIs, spironolactone/eplerenone, amiloride/triamterene, TMP (in TMP‑SMX), heparin, NSAIDs, tacrolimus/cyclosporine, pentamidine.
    • Drugs lowering K: Loop and thiazide diuretics, insulin, beta‑agonists, amphotericin B, high‑dose steroids.
    • Pseudo-hyperkalemia: Hemolyzed specimen, prolonged tourniquet, fist‑pumping, thrombocytosis. Repeat before treating.
    • What to do: K ≥5.5 mmol/L on RAAS inhibitors—review meds, add/adjust diuretic, consider potassium binder, or lower RAAS dose if needed; recheck within days.
  • Bicarbonate (CO₂ on BMP)
    • Low (metabolic acidosis): CKD, diarrhea, ketoacidosis, lactic acidosis. Drugs: topiramate/zonisamide, acetazolamide, metformin in AKI/hypoxia, salicylates (early respiratory alkalosis, later acidosis).
    • High (metabolic alkalosis): Vomiting, volume depletion. Drugs: loop/thiazide diuretics, licorice (mineralocorticoid effect).
  • BUN/Creatinine/eGFR
    • Why they matter: Dosing and nephrotoxicity. eGFR guides renal dose adjustments.
    • Drugs that reduce GFR (hemodynamic): NSAIDs constrict afferent arteriole; ACEi/ARBs dilate efferent arteriole. A small creatinine rise (up to ~30%) after ACEi/ARB start is expected.
    • Drugs that injure kidneys: Aminoglycosides, amphotericin B, cisplatin, methotrexate (crystal), tenofovir, IV contrast (AKI risk), high‑dose vancomycin, tacrolimus/cyclosporine.
    • Drugs that raise creatinine without harming GFR: Trimethoprim and cimetidine block tubular secretion; expect a mild reversible bump.
    • What to do: On ACEi/ARB, check creatinine and K 1–2 weeks after start or dose increase. For nephrotoxins, schedule baseline and repeat labs; ensure hydration and adjust doses.
  • Glucose
    • High: Steroids, atypical antipsychotics, calcineurin inhibitors, octreotide withdrawal, thiazides, niacin.
    • Low: Insulin/sulfonylureas, quinolones (rare), alcohol (poor intake). Beta‑blockers can mask symptoms.
    • SGLT2 note: Euglycemic DKA can occur—normal/mildly elevated glucose with acidosis and positive ketones. Look for nausea, abdominal pain, rapid breathing.
  • Calcium
    • High: Thiazides, lithium, vitamin D or calcium excess, granulomatous disease. Consider albumin correction or ionized calcium.
    • Low: Loop diuretics, calcitonin, bisphosphonates/denosumab, hypomagnesemia (PPIs can contribute).

Liver panel (AST, ALT, ALP, bilirubin, albumin)

Patterns matter: High AST/ALT suggest hepatocellular injury; high ALP±bilirubin suggests cholestasis; low albumin and high INR may reflect synthetic failure.

  • Drugs causing hepatocellular injury: Acetaminophen overdose, isoniazid, valproate, amiodarone, methotrexate, statins (usually mild asymptomatic ALT rise), anti‑TB combos, certain TKIs.
  • Drugs causing cholestasis: Amoxicillin‑clavulanate, anabolic steroids, chlorpromazine.
  • Alcohol pattern: AST:ALT ratio >2 suggests alcoholic injury.
  • What to do: If ALT/AST >3× ULN with symptoms or >5× ULN without symptoms on a suspect drug, hold the drug and evaluate. Re‑challenge only with clear indication and plan.

CBC: hemoglobin, white cells, platelets

Hemoglobin/Hematocrit: Low suggests anemia; check MCV for type. Drug links: bleeding (anticoagulants, antiplatelets), marrow suppression (chemotherapy), hemolysis (dapsone, high‑dose penicillins), nutrient interference (PPIs with iron/B12 absorption over time).

White blood cells/ANC: High with infection or steroids; low with marrow suppression.

  • Neutropenia causes: Clozapine (requires REMS ANC monitoring), carbimazole/methimazole and PTU, linezolid, TMP‑SMX, chemotherapy, felbamate.
  • What to do: Fever with ANC <500 is an emergency. For clozapine, follow hold/restart ANC thresholds.

Platelets: Low from marrow suppression or immune destruction.

  • Drug links: Heparin (HIT—platelets drop >50% from baseline), linezolid, valproate, gold salts, quinine/quinidine, GP IIb/IIIa inhibitors.
  • What to do: For suspected HIT, stop all heparin, switch to non‑heparin anticoagulant, confirm with testing.

Thyroid tests (TSH, free T4)

Reading them: High TSH with low free T4 means hypothyroidism. Low TSH with high free T4 means hyperthyroidism. TSH alone is often enough for dose titration once stable.

  • Drug effects: Amiodarone can cause hypo‑ or hyperthyroidism; lithium causes hypothyroidism; interferon and some TKIs can shift thyroid function.
  • Assay interference: High‑dose biotin can make TSH appear falsely low and free T4 falsely high. Hold biotin 48 hours before testing.
  • Levothyroxine absorption issues: Iron, calcium, PPIs, cholestyramine, sucralfate reduce absorption—separate by at least 4 hours. Enzyme inducers (phenytoin, carbamazepine) increase clearance.

What to do: If values don’t fit symptoms, ask about biotin and timing of dose vs lab draw. Recheck after holding biotin and adjusting timing.

Lipids (LDL‑C, HDL‑C, triglycerides)

Why they matter: Guide statin and adjunct therapy to cut ASCVD risk. Fasting is most important when triglycerides are very high or to diagnose familial disorders.

  • Drugs raising triglycerides: Alcohol, estrogens, beta‑blockers without ISA, isotretinoin, atypical antipsychotics, protease inhibitors.
  • Drugs lowering LDL: Statins (first‑line), ezetimibe, PCSK9 inhibitors, bempedoic acid.
  • What to do: If TG ≥500 mg/dL, reduce pancreatitis risk—address alcohol, add fibrate or high‑dose omega‑3s, and control secondary causes (uncontrolled diabetes, hypothyroidism).

Urinalysis and related checks

  • Glucosuria: Expected on SGLT2 inhibitors even with normal glucose. Not necessarily poor control.
  • Protein/albumin: ACEi/ARBs reduce albuminuria and protect kidneys—track response.
  • Hematuria: Can appear with anticoagulation; always rule out other causes if persistent.
  • Ketones: Positive with DKA; consider euglycemic DKA on SGLT2 if symptoms and acidosis are present.
  • Specific gravity: High suggests dehydration; impacts creatinine concentration for urine drug levels (e.g., vancomycin randoms in AKI workups).

Common drug level monitoring

  • Vancomycin: Use AUC‑guided dosing when possible; troughs are a proxy. High levels raise AKI risk, especially with piperacillin‑tazobactam.
  • Digoxin: Narrow therapeutic index. Hypokalemia increases toxicity risk; check K, Mg, and renal function.
  • Antiepileptics: Phenytoin is albumin‑bound—use corrected level in low albumin or measure free level. Valproate can cause thrombocytopenia and hyperammonemia.

Fast troubleshooting examples

  • Case 1: K rises to 5.6 after starting lisinopril + spironolactone
    • Why: Reduced renal K excretion via RAAS blockade on both sides.
    • Action: Stop or lower one agent, add loop diuretic if volume allows, consider a potassium binder, recheck K within 2–3 days.
  • Case 2: INR jumps to 4.1 two days after starting TMP‑SMX on warfarin
    • Why: CYP2C9 inhibition and gut flora vitamin K reduction.
    • Action: Hold/adjust warfarin per protocol, monitor closely during and after antibiotic, consider an alternate antibiotic next time.
  • Case 3: A1C 9.0% but CGM shows average glucose near goal
    • Why: Iron deficiency can falsely elevate A1C; or recent transfusion may distort results.
    • Action: Check CBC and iron studies; consider fructosamine; treat iron deficiency and recheck A1C later.
  • Case 4: TSH undetectable, free T4 high in a well patient taking hair/nail vitamins
    • Why: Biotin interference.
    • Action: Hold biotin 48 hours and repeat; avoid unnecessary levothyroxine changes.
  • Case 5: Creatinine rises 25% one week after ARB start
    • Why: Expected hemodynamic effect.
    • Action: If rise is ≤30% and K normal, continue and recheck; review NSAID use and hydration.

Practical checklist before you call the prescriber

  • Confirm the reference range and repeat unexpected results (especially potassium) to rule out specimen error.
  • Review new, stopped, or missed medications, OTCs, supplements (biotin, vitamin K), and alcohol.
  • Check timing: fasting status, time from dose to draw, and recent dose changes.
  • Assess kidney and liver function for dose adjustments and toxicity risk.
  • Look at the trend, not just the last value; note symptoms and vitals.

The right interpretation turns lab data into safer, sharper therapy. When a number moves, ask which drug could explain it, why the biology fits, and what action reduces risk while preserving benefit. That approach keeps patients safe and treatments effective.

Leave a Comment